These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
374 related articles for article (PubMed ID: 22163337)
21. Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG. Logan M; Law J; Wong JAJ; Hockman D; Landi A; Chen C; Crawford K; Kundu J; Baldwin L; Johnson J; Dahiya A; LaChance G; Marcotrigiano J; Law M; Foung S; Tyrrell L; Houghton M J Virol; 2017 Jan; 91(1):. PubMed ID: 27795422 [TBL] [Abstract][Full Text] [Related]
22. Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423. Keck ZY; Angus AG; Wang W; Lau P; Wang Y; Gatherer D; Patel AH; Foung SK PLoS Pathog; 2014 Aug; 10(8):e1004297. PubMed ID: 25122476 [TBL] [Abstract][Full Text] [Related]
23. Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2. Colbert MD; Flyak AI; Ogega CO; Kinchen VJ; Massaccesi G; Hernandez M; Davidson E; Doranz BJ; Cox AL; Crowe JE; Bailey JR J Virol; 2019 Jul; 93(14):. PubMed ID: 31068427 [TBL] [Abstract][Full Text] [Related]
24. Antibody Responses to Immunization With HCV Envelope Glycoproteins as a Baseline for B-Cell-Based Vaccine Development. Chen F; Nagy K; Chavez D; Willis S; McBride R; Giang E; Honda A; Bukh J; Ordoukhanian P; Zhu J; Frey S; Lanford R; Law M Gastroenterology; 2020 Mar; 158(4):1058-1071.e6. PubMed ID: 31809725 [TBL] [Abstract][Full Text] [Related]
25. Junctional and somatic hypermutation-induced CX Yi C; Xia J; He L; Ling Z; Wang X; Yan Y; Wang J; Zhao X; Fan W; Sun X; Zhang R; Ye S; Zhang R; Xu Y; Ma L; Zhang Y; Zhou H; Huang Z; Niu J; Long G; Lu J; Zhong J; Sun B Cell Mol Immunol; 2021 Mar; 18(3):675-685. PubMed ID: 32235917 [TBL] [Abstract][Full Text] [Related]
27. Virus-Like Particles Containing the E2 Core Domain of Hepatitis C Virus Generate Broadly Neutralizing Antibodies in Guinea Pigs. McGregor J; Hardy JM; Lay CS; Boo I; Piontek M; Suckow M; Coulibaly F; Poumbourios P; Center RJ; Drummer HE J Virol; 2022 Mar; 96(5):e0167521. PubMed ID: 34986001 [TBL] [Abstract][Full Text] [Related]
28. Defining Breadth of Hepatitis C Virus Neutralization. Kinchen VJ; Bailey JR Front Immunol; 2018; 9():1703. PubMed ID: 30116237 [TBL] [Abstract][Full Text] [Related]
29. The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigs. Vietheer PT; Boo I; Gu J; McCaffrey K; Edwards S; Owczarek C; Hardy MP; Fabri L; Center RJ; Poumbourios P; Drummer HE Hepatology; 2017 Apr; 65(4):1117-1131. PubMed ID: 27997681 [TBL] [Abstract][Full Text] [Related]
30. A Hepatitis C Virus DNA Vaccine Encoding a Secreted, Oligomerized Form of Envelope Proteins Is Highly Immunogenic and Elicits Neutralizing Antibodies in Vaccinated Mice. Masavuli MG; Wijesundara DK; Underwood A; Christiansen D; Earnest-Silveira L; Bull R; Torresi J; Gowans EJ; Grubor-Bauk B Front Immunol; 2019; 10():1145. PubMed ID: 31178869 [TBL] [Abstract][Full Text] [Related]
33. Mapping Determinants of Virus Neutralization and Viral Escape for Rational Design of a Hepatitis C Virus Vaccine. Keck ML; Wrensch F; Pierce BG; Baumert TF; Foung SKH Front Immunol; 2018; 9():1194. PubMed ID: 29904384 [TBL] [Abstract][Full Text] [Related]
34. Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles. Wasilewski LN; Ray SC; Bailey JR J Gen Virol; 2016 Nov; 97(11):2883-2893. PubMed ID: 27667373 [TBL] [Abstract][Full Text] [Related]
35. Standardized Method for the Study of Antibody Neutralization of HCV Pseudoparticles (HCVpp). Bailey JR; Urbanowicz RA; Ball JK; Law M; Foung SKH Methods Mol Biol; 2019; 1911():441-450. PubMed ID: 30593644 [TBL] [Abstract][Full Text] [Related]
36. Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies. Pantua H; Diao J; Ultsch M; Hazen M; Mathieu M; McCutcheon K; Takeda K; Date S; Cheung TK; Phung Q; Hass P; Arnott D; Hongo JA; Matthews DJ; Brown A; Patel AH; Kelley RF; Eigenbrot C; Kapadia SB J Mol Biol; 2013 Jun; 425(11):1899-1914. PubMed ID: 23458406 [TBL] [Abstract][Full Text] [Related]
37. Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants. Khera T; Behrendt P; Bankwitz D; Brown RJP; Todt D; Doepke M; Khan AG; Schulze K; Law J; Logan M; Hockman D; Wong JAJ; Dold L; Gonzalez-Motos V; Spengler U; Viejo-Borbolla A; Ströh LJ; Krey T; Tarr AW; Steinmann E; Manns MP; Klein F; Guzman CA; Marcotrigiano J; Houghton M; Pietschmann T J Hepatol; 2019 Apr; 70(4):593-602. PubMed ID: 30439392 [TBL] [Abstract][Full Text] [Related]
38. Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization. Tarr AW; Urbanowicz RA; Jayaraj D; Brown RJ; McKeating JA; Irving WL; Ball JK J Virol; 2012 Mar; 86(5):2739-49. PubMed ID: 22171278 [TBL] [Abstract][Full Text] [Related]
39. The hepatitis C virus glycan shield and evasion of the humoral immune response. Helle F; Duverlie G; Dubuisson J Viruses; 2011 Oct; 3(10):1909-32. PubMed ID: 22069522 [TBL] [Abstract][Full Text] [Related]
40. Design of a native-like secreted form of the hepatitis C virus E1E2 heterodimer. Guest JD; Wang R; Elkholy KH; Chagas A; Chao KL; Cleveland TE; Kim YC; Keck ZY; Marin A; Yunus AS; Mariuzza RA; Andrianov AK; Toth EA; Foung SKH; Pierce BG; Fuerst TR Proc Natl Acad Sci U S A; 2021 Jan; 118(3):. PubMed ID: 33431677 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]